These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32639326)

  • 1. Lipid-lowering nutraceuticals update on scientific evidence.
    Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A; Katsiki N; Karagiannis A; Athyros V
    Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
    Arnold SV; Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Alam S; Mues KE; Bhatt DL; Kosiborod M;
    J Am Heart Assoc; 2021 Aug; 10(16):e020893. PubMed ID: 34369165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM; Aguiar C; Morais J;
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
    Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
    Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 16. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.
    Patti AM; Katsiki N; Nikolic D; Al-Rasadi K; Rizzo M
    Angiology; 2015 May; 66(5):416-21. PubMed ID: 25037700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 20. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.